Besides, miR-149-3p was the downstream target of METTL1 [10], and overexpression of miR-149-3p decreased chemoresistance of multiple cancers to cisplatin, such as ovarian cancer [18], esophageal cancer [19], gastric cancer [20] and non-small cell lung cancer [21]. This evidence concerns the gene METTL1 and ovarian carcinoma.